News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
671,093 Results
Type
Article (34040)
Company Profile (641)
Press Release (636412)
Multimedia
Podcasts (86)
Webinars (12)
Section
Business (203296)
Career Advice (2190)
Deals (37190)
Drug Delivery (109)
Drug Development (80673)
Employer Resources (167)
FDA (15764)
Job Trends (15029)
News (343922)
Policy (30275)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (6)
2025 BioForest Digital (6)
2025 Lone Star Bio Digital (10)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (1342)
Academic (1)
Accelerated approval (5)
Adcomms (15)
Allergies (84)
Alliances (48954)
ALS (95)
Alzheimer's disease (1325)
Antibody-drug conjugate (ADC) (143)
Approvals (15750)
Artificial intelligence (256)
Autoimmune disease (28)
Automation (15)
Bankruptcy (380)
Best Places to Work (11062)
BIOSECURE Act (22)
Biosimilars (104)
Biotechnology (438)
Bladder cancer (76)
Brain cancer (27)
Breast cancer (251)
Cancer (2124)
Cardiovascular disease (173)
Career advice (1807)
Career pathing (32)
CAR-T (150)
Cell therapy (432)
Cervical cancer (17)
Clinical research (66090)
Collaboration (854)
Compensation (528)
Complete response letters (29)
COVID-19 (2231)
CRISPR (45)
C-suite (255)
Cystic fibrosis (100)
Data (2110)
Decentralized trials (2)
Denatured (16)
Depression (49)
Diabetes (254)
Diagnostics (6358)
Digital health (18)
Diversity (3)
Diversity, equity & inclusion (38)
Drug discovery (117)
Drug pricing (108)
Drug shortages (27)
Duchenne muscular dystrophy (90)
Earnings (85560)
Editorial (39)
Employer branding (24)
Employer resources (142)
Events (112717)
Executive appointments (742)
FDA (16943)
Featured Employer (64)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (744)
Gene editing (112)
Generative AI (25)
Gene therapy (312)
GLP-1 (742)
Government (3064)
Grass and pollen (6)
Guidances (48)
Healthcare (16092)
Huntington's disease (23)
IgA nephropathy (29)
Immunology and inflammation (128)
Indications (29)
Infectious disease (2368)
Inflammatory bowel disease (138)
Inflation Reduction Act (9)
Influenza (50)
Intellectual property (98)
Interviews (434)
IPO (17355)
IRA (45)
Job creations (4414)
Job search strategy (1508)
Kidney cancer (10)
Labor market (37)
Layoffs (538)
Leadership (18)
Legal (7690)
Liver cancer (72)
Lung cancer (305)
Lymphoma (138)
Machine learning (4)
Management (59)
Manufacturing (328)
MASH (70)
Medical device (13579)
Medtech (13584)
Mergers & acquisitions (20383)
Metabolic disorders (684)
Multiple sclerosis (83)
NASH (21)
Neurodegenerative disease (103)
Neuropsychiatric disorders (32)
Neuroscience (1885)
NextGen: Class of 2025 (6038)
Non-profit (2034)
Northern California (2661)
Now hiring (40)
Obesity (369)
Opinion (253)
Ovarian cancer (69)
Pain (93)
Pancreatic cancer (80)
Parkinson's disease (150)
Partnered (19)
Patents (239)
Patient recruitment (106)
Peanut (48)
People (57976)
Pharmaceutical (133)
Pharmacy benefit managers (17)
Phase I (20666)
Phase II (29410)
Phase III (21884)
Pipeline (1188)
Policy (142)
Postmarket research (2138)
Preclinical (8469)
Press Release (64)
Prostate cancer (103)
Psychedelics (36)
Radiopharmaceuticals (262)
Rare diseases (391)
Real estate (6028)
Recruiting (65)
Regulatory (21504)
Reports (35)
Research institute (1394)
Resumes & cover letters (342)
Rett syndrome (5)
RNA editing (5)
RSV (44)
Schizophrenia (76)
Series A (136)
Series B (90)
Service/supplier (26)
Sickle cell disease (54)
Southern California (2269)
Special edition (16)
Spinal muscular atrophy (148)
Sponsored (22)
Startups (3935)
State (2)
Stomach cancer (14)
Supply chain (72)
Tariffs (43)
The Weekly (68)
United States (23058)
Vaccines (659)
Venture capitalists (44)
Weight loss (251)
Women's health (25)
Worklife (19)
Date
Today (222)
Last 7 days (895)
Last 30 days (2714)
Last 365 days (33459)
2025 (10601)
2024 (35957)
2023 (40682)
2022 (51209)
2021 (54624)
2020 (51619)
2019 (42552)
2018 (32492)
2017 (33104)
2016 (31455)
2015 (36935)
2014 (30162)
2013 (25293)
2012 (26877)
2011 (27035)
2010 (25026)
Location
Africa (697)
Alabama (59)
Alaska (6)
Arizona (172)
Arkansas (11)
Asia (42913)
Australia (6864)
California (6169)
Canada (1998)
China (538)
Colorado (265)
Connecticut (280)
Delaware (141)
Europe (90244)
Florida (860)
Georgia (201)
Hawaii (1)
Idaho (56)
Illinois (469)
India (28)
Indiana (319)
Iowa (12)
Japan (155)
Kansas (100)
Kentucky (23)
Louisiana (11)
Maine (65)
Maryland (786)
Massachusetts (4779)
Michigan (231)
Minnesota (392)
Mississippi (2)
Missouri (80)
Montana (30)
Nebraska (22)
Nevada (58)
New Hampshire (66)
New Jersey (1736)
New Mexico (30)
New York (1712)
North Carolina (1065)
North Dakota (7)
Northern California (2661)
Ohio (187)
Oklahoma (10)
Oregon (41)
Pennsylvania (1343)
Puerto Rico (13)
Rhode Island (35)
South America (1097)
South Carolina (21)
South Dakota (1)
Southern California (2269)
Tennessee (83)
Texas (884)
Utah (179)
Virginia (143)
Washington D.C. (59)
Washington State (570)
West Virginia (3)
Wisconsin (53)
671,093 Results for "ono pharmaceutical company ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.
February 17, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge of late-stage development as well as regulatory and commercialization activities.
March 12, 2025
·
2 min read
·
Tristan Manalac
Deals
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, “Ono”) today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc.
June 11, 2024
·
5 min read
Press Releases
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
March 12, 2025
·
3 min read
Press Releases
Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
·
2 min read
Deals
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.
April 29, 2024
·
10 min read
Deals
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024, ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.
April 30, 2024
·
10 min read
Press Releases
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
April 21, 2025
·
3 min read
Press Releases
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
March 12, 2025
·
5 min read
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
PRISM BioLab, Co. Ltd. announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD.
April 25, 2024
·
3 min read
1 of 67,110
Next
